Gastric Retention
10
1
1
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
10%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores
the Effect of Abdominal Massage on the Gastric Residual Volume.
Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects
Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults
Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults
Multi-Center Study of Different Doses Domperidone in Feeding Intolerance